Digest Network Come funziona
Network
/
Società
Te
Non verificato

Teva Pharmaceutical Industries Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

124 comunicati stampa

Guarda tutti i comunicati
14/09/2026
Farmaceutica
Finanza
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
10/09/2026
Farmaceutica
Fondi di investimento
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
07/09/2026
Farmaceutica
Finanza
Teva Announces Launch of Offering of Senior Notes
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
04/09/2026
Farmaceutica
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
02/09/2026
Farmaceutica
Medicina Salute Benessere
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
01/09/2026
Farmaceutica
Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
31/08/2026
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
28/08/2026
Farmaceutica
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy 
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
19/08/2026
Farmaceutica
Medicina Salute Benessere
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
11/08/2026
Farmaceutica
Annunci Economici
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0